Utility Therapeutics gets FDA nod for drug to fight urinary tract infections
HQ Team April 25, 2024: The US health regulator has approved a drug of Utility Therapeutics to treat adult women, 18 years or.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team April 25, 2024: The US health regulator has approved a drug of Utility Therapeutics to treat adult women, 18 years or.
HQ Team April 9, 2024: Pfizer Inc., announced its experimental drug for treating a lower respiratory tract disease for adults between 18- to.
HQ Team April 4, 2024: Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the.
HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.
HQ Team April 1, 2024: Preventing the spread of sexually transmitted infections (STIs) might soon be as simple as taking a couple of.
HQ Team March 29, 2024: Bristol Myers Squibb’s final stage clinical trials for its Zeposia oral drug, to treat moderate to severe Crohn’s.
US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.
HQ Team March 25, 2024: Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.
HQ Team March 19, 2024: Bayer AG, a German pharmaceutical major, will seek regulatory approval for its menopausal drug after the final trials.
HQ Team March 12, 2024: Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com